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ABSTRACT
Alterations in p16 protein expression have been reported to be associated 
with tumor development and progression. However, p16 expression status in the 
peritumoral stroma has been rarely investigated. We investigated the stromal p16 
expression in ovarian neoplasms using immunohistochemistry, and differences in 
the expression status depending on the degree of malignancy and histological type 
were analyzed. This study included 24, 21, and 46 cases of benign, borderline, and 
malignant ovarian lesions, respectively, of which 29, 25, and 32 cases were serous, 
mucinous, and endometriosis-associated lesions. Most benign lesions showed negative 
or weak expression, whereas borderline lesions showed focal, moderate expression. 
Malignant lesions showed markedly elevated stromal p16 expression compared 
with benign or borderline lesions. There were significant differences in stromal p16 
expression between benign and borderline lesions (P < 0.001) and between borderline 
and malignant lesions (P < 0.001). These significances remained when analysis was 
performed based on lesion classification as serous, mucinous, and endometriosis-
associated. In contrast, differences in stromal p16 expression among the histological 
types were not significant. Stromal p16 expression in ovarian neoplasms was absent 
or weak in benign and focal, moderate in borderline lesions, whereas malignant 
lesions exhibited diffuse, moderate-to-strong p16 immunoreactivity. Our observations 
suggest that stromal p16 expression is involved in the development of ovarian 
carcinoma. Further studies are necessary to confirm our preliminary results.
INTRODUCTION
p16 is the principal member of the INK4 family 
of cyclin-dependent kinase (CDK) inhibitors [1]. As a 
regulatory protein of the cell cycle, p16 is involved in the 
G1-to-S phase transition. Upon binding to CDK4/6, p16 
inhibits formation of the cyclin D1-CDK4/6 complex and 
CDK4/6-mediated phosphorylation of the retinoblastoma 
(RB) protein. Once RB is phosphorylated, the E2F-
RB complex dissociates, leading to reduced growth-
suppressor activity of RB [2]. Like RB, p16 is known as 
a tumor suppressor. p16 maintains RB family members in 
a hypophosphorylated state [2-5]. However, it is difficult 
to explain many aspects of p16 function and regulation by 
its well-known function as a tumor suppressor alone. In 
addition, molecular pathways responsible for p16 function 
and expression have not yet been determined.
Conflicting patterns of p16 expression have been 
reported, which further complicates the understanding 
of its biological and pathological roles. In different 
types of neoplasms, p16 expression is either lost or 
downregulated [6-9], or clearly overexpressed [10-13]. 
p16 expression has been analyzed in some studies of 
gynecological malignancy. According to the 2014 World 
Health Organization (WHO) Blue Book, 60% of ovarian 
high-grade serous carcinomas show diffuse, strong p16 
expression [14]. p16 and p53 expression levels are used 
as differential markers to distinguish high-grade serous 
carcinoma from other histological types of ovarian 
carcinoma. It is well known that p16 overexpression 
occurs in human papillomavirus (HPV)-related tumors [1, 
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14]. p16 overexpression indicates high-risk HPV infection, 
not only in uterine cervical carcinoma and head and neck 
carcinoma, but also in high-grade squamous intraepithelial 
lesions (HSILs) of the vulvovaginal and anogenital 
regions; therefore, p16 is used as a diagnostic marker for 
both HSIL and invasive squamous cell carcinoma [1, 15]. 
Similarly, in breast carcinoma, high p16 immunoreactivity 
is significantly correlated with more undifferentiated and 
malignant phenotypes (i.e., estrogen receptor negativity 
and higher nuclear grade) [13]. Moreover, p16 staining 
intensity and expression are significantly higher in uterine 
leiomyosarcoma compared with benign uterine leiomyoma 
or uterine smooth muscle tumors of uncertain malignant 
potential [16].
 Recently, during the routine diagnosis of surgically 
resected ovarian neoplasms, we noticed p16 expression in 
the peritumoral stroma. The levels of p16 expression in the 
stromal cells varied depending on degree of malignancy 
and histological type. Although p16 is commonly used as a 
biomarker for diagnosing gynecological malignancies, its 
expression in the stromal component of ovarian neoplasms 
has never been studied. In this study, we examined stromal 
p16 expression in benign, borderline, and malignant 
ovarian neoplasms by immunohistochemistry to determine 
whether a significant difference exists in stromal p16 
immunoreactivity according to degree of malignancy and/
or histological type.
RESULTS
Patient demographics
This preliminary study was conducted with 91 
patients who underwent surgical excision for benign, 
borderline, or malignant neoplasms of the ovary from 
March 2015 to May 2016. The age of patients ranged from 
23 to 61 years (median, 42 years) in patients with benign 
lesions, from 25 to 66 years (median, 48 years) in patients 
with borderline lesions, and from 28 to 82 years (median, 
53 years) in patients with malignant lesions. None of the 
patients received pre-operative neoadjuvant chemotherapy, 
radiation therapy, or concurrent chemoradiation therapy. 
Classification of all 91 cases according to degree 
of malignancy of ovarian neoplasms resulted in 24 
(26.4%) cases in the benign group, 21 (23.1%) cases 
in the borderline group, and 46 (50.5%) cases in the 
malignant group. According to histological type, the 91 
cases were classified into serous type (29 cases; 31.9%), 
mucinous type (25 cases; 27.5%), Brenner type (5 cases; 
5.5%), and endometrioid-associated type (32 cases; 
35.2%). The endometriosis-associated type included the 
endometrioid type (17 cases; 53.1%), clear cell type (8 
cases; 25.0%), and seromucinous type (7 cases; 21.9%). 
Seromucinous tumors are defined as benign cystic 
neoplasm (seromucinous cystadenoma), non-invasive, 
proliferative epithelial neoplasm (seromucinous borderline 
Figure 1: Stromal p16 overexpression in benign ovarian tumors. A. Serous cystadenoma. B. A few stromal cells displayed faint 
p16 immunoreactivity. C. Mucinous cystadenoma. D. Some scattered inflammatory cells were positive for p16. E. Endometriotic cyst. F. 
Some endometrial-type epithelial cells exhibited weak cytoplasmic p16 immunoreactivity. G. Benign Brenner tumor. H. Evident lack of 
stromal p16 expression.
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tumor, formerly known as endocervical-type or Mullerian 
mucinous borderline tumor) or carcinoma (seromucinous 
carcinoma) with two or more epithelial cell types, all 
accounting for at least 10% of the epithelium. The 
epithelium lining the cysts or papillae is composed mostly 
of serous or endocervical-type mucinous epithelium, but 
endometrioid, squamous, and clear cells may be seen 
[14]. Histological types were classified following the 
criteria of the WHO Classification of Tumours of Female 
Reproductive Organs, revised in 2014 [14]. 
Stromal p16 expression in benign, borderline, and 
malignant ovarian neoplasms
p16 immunostaining scores of benign, borderline, 
and malignant ovarian neoplasms are presented in Table 
1. Representative photomicrographs of stromal p16 
expression in benign ovarian neoplasms are presented 
in Figure 1. All 24 cases of benign ovarian neoplasm 
showed a p16 immunostaining score of 3 or less. Of the 
24 cases of benign lesions, 14 (58.3%) cases showed no 
p16 expression, whereas 7 (29.2%) cases, 2 (8.3%) cases, 
and 1 (4.2%) case had scores of 1, 2, and 3, respectively. 
No significant difference was observed in stromal p16 
expression status among the different histological types 
(P = 0.688). Of 6 cases of endometriotic cysts, 4 (66.7%) 
were found to have patchy and weak cytoplasmic p16 
immunoreactivity in endometrial-type epithelial cells 
lining the cystic space. Similarly, 1 of 3 (33.3%) benign 
Brenner tumors showed patchy and weak p16 expression 
in the tumor cell cytoplasm.
Representative photomicrographs of stromal p16 
expression in borderline ovarian neoplasms are presented 
in Figure 2. Of the 21 cases of borderline ovarian 
neoplasms, 12 (57.1%) showed p16 immunostaining 
scores of 3 or greater. Two (28.6%) cases of serous 
borderline tumor and 2 (25.0%) mucinous borderline 
tumors had p16 immunostaining scores of 4. While p16 
immunostaining scores of serous and mucinous types 
Table 1: Stromal p16 expression in benign, borderline, and malignant ovarian lesions
Category Pathological diagnosis
Total p16 immunostaining score P 
value
0 1 2 3 4 6 9
Benign Serous cystadenoma/adenofibroma 6 4 (66.6) 1 (16.7) 1 (16.7) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0.688
Mucinous cystadenoma/
adenofibroma 7 4 (57.1) 2 (28.6) 0 (0.0) 1 (14.3) 0 (0.0) 0 (0.0) 0 (0.0)
Endometriosis/endometrioid 
cystadenoma 6 2 (33.3) 3 (50.0) 1(16.7) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Benign Brenner tumor 3 3(100.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Seromucinous cystadenoma 2 1 (50.0) 1 (50.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Borderline Serous borderline tumor 7 0 (0.0) 1 (14.3) 2 (28.6) 2 (28.6) 2 (28.6) 0 (0.0) 0 (0.0) 0.662
Mucinous borderline tumor 8 0 (0.0) 1 (12.5) 2 (25.0) 3 (37.5) 2 (25.0) 0 (0.0) 0 (0.0)
Endometrioid borderline 
tumor 2 0 (0.0) 0 (0.0) 1 (50.0) 1 (50.0) 0 (0.0) 0 (0.0) 0 (0.0)
Borderline Brenner tumor 1 0 (0.0) 0 (0.0) 1 (100.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Seromucinous borderline 
tumor 2 0 (0.0) 0 (0.0) 0 (0.0) 2 (100.0) 0 (0.0) 0 (0.0) 0 (0.0)
Clear cell borderline tumor 1 0 (0.0) 0 (0.0) 1 (100.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Malignant High-grade serous carcinoma 12 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (8.3) 7 (58.4) 4 (33.3) 0.648
Low-grade serous carcinoma 4 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (25.0) 3 (75.0) 0 (0.0)
Mucinous carcinoma 10 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 4 (40.0) 6 (60.0)
Endometrioid carcinoma 9 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (11.1) 8 (88.9)
Malignant Brenner tumor 1 0(0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (100.0)
Seromucinous carcinoma 3 0(0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 2 (66.7) 1 (33.3)
Clear cell carcinoma 7 0(0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (14.3) 4 (57.1) 2 (28.6)
Table 2: Differences in stromal p16 expression between benign, borderline, and malignant ovarian lesions
Category Total p16 immunostaining score P value0 1 2 3 4 6 9
Benign 24 14 (58.3) 7 (29.2) 2 (8.3) 1 (4.2) 0 (0.0) 0 (0.0) 0 (0.0)
Borderline 21 0 (00.0) 2 (9.5) 7 (33.3) 8 (38.1) 4 (19.1) 0 (0.0) 0 (0.0) <0.001a
Malignant 46 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 3 (6.5) 21 (45.7) 22 (47.8) <0.001b
aBenign versus borderline; bBorderline versus malignant
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varied from 1 to 4, those of the other 4 histological 
types were 2 or 3. These results might reflect the smaller 
number of cases with these histological types compared 
with the serous or mucinous types. Consistent with the 
benign lesions, no significant difference was observed 
in stromal p16 expression status among the different 
histological types of borderline ovarian neoplasms (P = 
0.662). Even though 2 (28.6%) serous borderline tumors, 
1 (50.0%) endometrioid borderline tumor, and 1 (50.0%) 
seromucinous borderline tumor exhibited moderate-to-
strong p16 staining intensity in the tumor cells, none of 
the cases showed diffuse expression.
Representative photomicrographs of stromal p16 
expression in malignant ovarian neoplasms are presented 
in Figure 3. Of the 24 cases of benign ovarian neoplasms 
and the 21 cases of borderline ovarian neoplasms, only 
4 (8.9%) borderline lesions showed p16 immunostaining 
scores of 4 or more, whereas all 46 (100.0%) cases of 
malignant ovarian neoplasms showed p16 immunostaining 
scores of 4 or greater. Moreover, 43 (93.5%) cases showed 
p16 immunostaining scores of 6 or greater. For 6 (60.0%) 
cases of mucinous carcinoma and 8 (88.9%) cases of 
endometrioid carcinoma, p16 expression in the stroma was 
diffuse and strong, with an immunostaining score of 9.
Differences in stromal p16 expression according 
to degree of malignancy of ovarian neoplasms
The mean p16 immunostaining scores of benign, 
borderline, and malignant ovarian neoplasms were 
0.6, 2.7 and 7.3, respectively. To analyze differences in 
stromal p16 expression between groups classified by 
degree of malignancy, a linear-by-linear association test 
was performed (Table 2). A significant difference was 
observed in stromal p16 expression between the benign 
and borderline groups (P < 0.001). Moreover, stromal p16 
expression differed significantly between the borderline 
and malignant groups (P < 0.001). The linear-by-linear 
association test performed according to the histological 
type of each group also revealed statistical significances 
between the benign and borderline (P = 0.008) and the 
borderline and malignant (P < 0.001) serous neoplasms 
(Table 3). For the mucinous type, a significant difference 
was also noted in stromal p16 expression when comparing 
the benign and borderline groups with the borderline and 
malignant mucinous neoplasms (P = 0.008 for benign 
versus borderline and P < 0.001 for borderline versus 
malignant). In addition, endometriosis-associated types 
showed consistent stromal p16 expression patterns 
according to degree of malignancy (P = 0.004 for benign 
Table 3: Differences in stromal p16 expression between benign, borderline, and malignant ovarian lesions for each 
histological type
Histological type Category
Total p16 immunostaining score
P value
0 1 2 3 4 6 9
Serous Benign 6 4 (66.6) 1 (16.7) 1 (16.7) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Borderline 7 0 (0.0) 1 (14.2) 2 (28.6) 2 (28.6) 2 (28.6) 0 (0.0) 0 (0.0) 0.008a
Malignant 16 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 2 (12.5) 10(62.5) 4 (25.0) <0.001b
Mucinous Benign 7 4 (57.1) 2 (28.6) 0 (0.0) 1 (14.3) 0 (0.0) 0 (0.0) 0 (0.0)
Borderline 8 0 (0.0) 1 (12.5) 2 (25.0) 3 (37.5) 2 (25.0) 0 (0.0) 0 (0.0) 0.008a
Malignant 10 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 4 (40.0) 6 (60.0) <0.001b
Brenner Benign 3 3(100.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Borderline 1 0 (0.0) 0 (0.0) 1(100.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) Not performedc
Malignant 1 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1(100.0) Not performedc
Endometriosis-associatedd
Benign 8 3 (37.5) 4 (50.0) 1 (12.5) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Borderline 5 0 (0.0) 0 (0.0) 2 (40.0) 3 (60.0) 0 (0.0) 0 (0.0) 0 (0.0) 0.004a
Malignant 19 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (5.3) 7 (36.8) 11(57.9) <0.001b
aBenign versus borderline; bBorderline versus malignant; cDue to low sample size; dEndometriosis-associated type includes 
endometrioid, clear cell, and seromucinous types.
Table 4: Differences in stromal p16 expression between histological types
Histological type
Total p16 immunostaining score P value
0 1 2 3 4 6 9
Serous 29 4 (13.8) 2 (6.9) 3 (10.3) 2 (6.9) 4 (13.8) 10(34.5) 4 (13.8)
Mucinous 25 4 (16.0) 3 (12.0) 2 (8.0) 4 (16.0) 2 (8.0) 4 (16.0) 6 (24.0) 0.863a
Brenner 5 3 (60.0) 0 (0.0) 1 (20.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (20.0) 0.150a 0.237b
Endometriosis-associatedd 32 3 (9.4) 4 (12.5) 3 (9.4) 3 (9.4) 1 (3.1) 7 (21.9) 11 (34.4) 0.337a 0.306b 0.089c
Versus aserous, bmucinous, and cBrenner type; dEndometriosis-associated type includes endometrioid, clear cell, and 
seromucinous types.
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versus borderline; P < 0.001 for borderline versus 
malignant). However, statistical analysis could not be 
conducted on Brenner type due to the small number of 
cases.
Difference in stromal p16 expression between 
histological types
When ovarian neoplasms were classified by 
histological type without considering degree of 
malignancy, the p16 immunostaining scores varied from 
0 to 9 points (Table 4). The mean p16 immunostaining 
scores of serous, mucinous, Brenner, and endometriosis-
associated ovarian neoplasms were 4.3, 4.2, 2.2, and 5.4, 
respectively. No significant difference in stromal p16 
expression was observed among the histological types. In 
addition, there was no statistically significant difference 
in stromal p16 expression between high-grade serous 
carcinomas and non-high-grade serous carcinomas (P = 
0.267).
DISCUSSION
A novel finding reported in this preliminary study 
is the gradual and significant increase in stromal p16 
expression with increased degree of malignancy in benign, 
borderline, and malignant ovarian neoplasms. Consistent 
with this finding, comparing p16 expression within 
tumors of each histological type also revealed significant 
Figure 2: Stromal p16 overexpression in borderline ovarian tumors. A. Serous borderline tumor. B. Tumor cells displaying 
patchy but strong cytoplasmic p16 immunoreactivity. p16 expression was weaker in stromal cells than in tumor cells. C. Serous borderline 
tumor, another case. D. In this case, the tumor cells did not react with a p16 antibody. Spindle- or stellate-shaped stromal cells exhibited 
weak-to-moderate p16 immunoreactivity. E. Mucinous borderline tumor. F. Similar to the serous borderline tumors, most stromal cells 
showed weak cytoplasmic p16 immunoreactivity. G. Endometrioid borderline tumor. H. Some tumor cells, as well as the central squamous 
morule, displayed weak cytoplasmic p16 immunoreactivity. Focal, moderate p16 expression was observed in the stroma. I. Borderline 
Brenner tumor. J. Lack of p16 expression in tumor cells. Stromal cells showed patchy, moderate p16 immunoreactivity. K. Seromucinous 
borderline tumor. L. A few tumor cells showed strong nuclear p16 immunoreactivity. The stromal cells displayed weak cytoplasmic p16 
immunoreactivity.
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differences; in serous, mucinous, and endometriosis-
associated neoplasms, stromal p16 expression in 
malignant and borderline lesions was significantly higher 
than that of borderline and benign lesions, respectively. 
In contrast, no significant difference was observed in 
stromal p16 expression among histological types. Our 
Figure 3: Stromal p16 overexpression in malignant ovarian tumors. A.-D. High-grade serous carcinoma. B. The tumor cells 
demonstrated strong nuclear and cytoplasmic p16 expression. The spindle-shaped stromal cells displayed the same degree of p16 staining 
intensity as the tumor cells. C. High-grade serous carcinoma. D. In another high-grade serous carcinoma case, the stromal cells exhibited 
moderate-to-strong p16 expression, both in their nuclei and cytoplasm. E. Low-grade serous carcinoma. F. p16 immunostaining highlighted 
the stromal cells, which expressed p16 uniformly. G. Mucinous carcinoma with a destructive stromal-invasive pattern. H. Both tumor 
cells (lower right corner) and stromal cells (upper left corner) strongly expressed p16. I. Endometrioid carcinoma. J. The hypercellular 
stroma showed diffuse, intense p16 immunoreactivity. K. Malignant Brenner tumor. L. p16 immunostaining highlighted the stroma, which 
separated into irregular-shaped tumor cell nests and sheets. M. Clear cell carcinoma. N. The tumor cells (lower right corner) displayed 
weak cytoplasmic p16 expression, whereas the stromal cells (left half) showed moderate-to-strong nuclear p16 immunoreactivity. O. 
Seromucinous carcinoma. P. Similar to high-grade serous carcinoma, the tumor cells strongly reacted with p16. The stromal cells showed 
diffuse, moderate p16 staining.
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observation of significantly higher levels of stromal p16 
expression in malignant ovarian lesions suggests that p16 
may be involved in tumor cell growth and invasion in the 
tumor microenvironment through its overexpression in 
stromal cells. Some previous studies have reported p16 
overexpression at the invasive tumor front of endometrial 
carcinoma, colorectal carcinoma, and basal cell carcinoma 
[17-20]. These results suggest that p16 may be involved 
in tumor invasion and angiogenesis and support the 
hypothesis that the p16 protein promotes invasiveness 
through interactions with other molecules related with 
tumor cell migration and invasion [1, 17-19, 21]. To 
confirm our preliminary results, it will be necessary to 
analyze stromal p16 expression using a larger number of 
ovarian carcinoma samples.
We found two previous studies reporting stromal 
p16 expression and its clinical implications in breast 
carcinoma [22] and endometrial neoplastic lesions [23]. 
For 80.0% (28/35) of endometrial polyp cases, p16 
immunoreactivity with moderate or greater intensity was 
observed in fibrous stroma, and 1 (3.0%; 1/33) case of 
endometrial hyperplasia showed weak p16 expression; 
however, none of the endometrial carcinoma cases 
(0.0%; 0/23) showed stromal p16 expression. Moritani 
and colleagues [23] stated that stromal p16 expression 
was a characteristic finding of endometrial polyps 
and was useful in differentiating between endometrial 
hyperplasia and endometrial polyps. These results 
were inconsistent with our findings that stromal p16 
expression was significantly higher in borderline and 
malignant lesions than in benign lesions. We attribute 
these differences to the following two reasons. First, two 
different sets of tissue samples (ovary and endometrium) 
were used, and stromal p16 expression patterns may be 
organ-specific. Second, p16 overexpression was reported 
to be observed in benign tumors such as benign nevus, 
neurofibroma, and schwannoma, which are known to be 
related to oncogene-induced cellular senescence [23]. 
Thus, p16 overexpression in benign lesions inhibited 
cellular proliferation, protecting cells from malignant 
transformation [1]. Significantly higher rates of stromal 
p16 overexpression in endometrial polyps can be 
explained by oncogene-induced cellular senescence. In 
contrast, in this study, malignant lesions showed a higher 
level of stromal p16 expression, which might be due to 
a positive feedback mechanism caused by RB protein 
deregulation. A study on p16 expression in the stroma 
of ductal carcinoma in situ of the breast [22] provided 
evidence that DCIS with high stromal p16 expression 
tended to show estrogen receptor negativity and high Ki-
67 labeling indices. In addition, it was reported that high 
stromal p16 expression was a strong independent predictor 
of ductal carcinoma in situ recurrence with a higher hazard 
ratio than the established prognostic markers. These 
findings are in agreement with our data. p16 is an inhibitor 
of cell growth in response to various stress stimuli, such 
as DNA damage, oxidative stress, or hyperproliferative 
signals. Therefore, the p16 protein induces cellular 
senescence, such that stromal p16 overexpression is 
indicative of stromal cell senescence. Based on results 
of previous studies, [23-25], however, we postulated that 
senescent stroma can contribute to disease progression by 
secreting inflammatory mediators, cytokines, and enzymes 
such as proteases, providing a mechanism through which 
p16-positive stroma contributes to tumor progression and/
or invasion.
In conclusion, we demonstrated that stromal 
p16 expression of malignant ovarian neoplasms was 
significantly higher than that of borderline ovarian 
neoplasms, which in turn was significantly higher than that 
of benign ovarian neoplasms. Stromal p16 expression was 
absent or weak in benign lesions, whereas the majority 
of malignant lesions exhibited diffuse and moderate-to-
strong p16 immunoreactivity, suggesting that stromal 
p16 expression can be used as an adjunctive biomarker 
reflecting the development of ovarian carcinoma. Further 
studies are necessary to confirm our preliminary results.
MATERIALS AND METHODS
Tissue specimens
Ninety-one cases of ovarian lesions were retrieved 
from the surgical pathology files of Severance Hospital 
from March 2015 to May 2016. The pathological 
diagnoses are summarized in Table 1. Ovarian lesions 
were classified as benign, borderline, and malignant in 24, 
21, and 46 cases, respectively. The age of patients ranged 
from 23 to 82 years (median, 50 years). Of the 24 cases of 
benign lesions, 11, 7, and 6 cases were diagnosed during 
bilateral salpingo-oophorectomy, unilateral salpingo-
oophorectomy, and partial oophorectomy, respectively. 
Of the 21 cases of borderline lesions, 9, 8, and 4 cases 
were diagnosed during abdominal total hysterectomy 
with bilateral salpingo-oophorectomy, bilateral salpingo-
oophorectomy, and unilateral salpingo-oophorectomy, 
respectively. Thirty-nine of the 46 malignant lesions cases 
were diagnosed in a primary debulking surgery (including 
laparoscopic or abdominal total hysterectomy, bilateral 
salpingo-oophorectomy, pelvic and/or para-aortic lymph 
node dissection, total omentectomy, and/or tumorectomy), 
and the remaining 7 cases were diagnosed in a unilateral 
salpingo-oophorectomy. This study did not include any 
cases where the histological differential diagnosis between 
benign and borderline lesions was ambiguous. This study 
was reviewed and approved by the Institutional Review 
Board at Severance Hospital, Yonsei University Health 
System, Seoul, Republic of Korea (2016-0931-001).
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Histopathological examination
The resection specimens were fixed in 10% neutral-
buffered formalin and embedded in paraffin blocks. 
From each formalin-fixed, paraffin-embedded block, 
4-μm sections were cut and stained with hematoxylin 
and eosin. Two independent pathologists examined all 
available hematoxylin and eosin-stained slides by routine 
light microscopy and chose the most representative 
formalin-fixed, paraffin-embedded block to perform 
immunohistochemical staining.
Immunohistochemical staining
The formalin-fixed, paraffin-embedded sections 
were deparaffinized and rehydrated with a xylene and 
alcohol solution. Immunohistochemical staining was 
performed using a Ventana Benchmark XT automated 
staining system (Ventana Medical Systems, Tucson, 
AZ, USA), according to the manufacturer’s instructions. 
Antigen retrieval was performed using Cell Conditioning 
Solution (CC1; Ventana Medical Systems). Sections 
were incubated with primary antibodies against p16 (pre-
diluted, clone E6H4, Ventana Medical Systems). After 
chromogenic visualization, using UltraView Universal 
DAB Detection Kits (Ventana Medical Systems), slides 
were counterstained with hematoxylin. Appropriate 
positive and negative controls were concurrently stained 
to validate the staining method.
The percentage of p16-positive stromal cells and 
the staining intensity were assessed. A cut-off index was 
defined as the presence of 10% or more cells displaying 
nuclear p16 immunoreactivity, as previously described 
[23, 26]. The estimated percentages were categorized 
as follows: less than 10% (score 0), 10% to 24% (score 
1), 25% to 50% (score 2), or 50% or more (score 3). The 
staining intensity was graded as follows: negative (score 
0), weak (score 1), moderate (score 2), or strong (score 3). 
The subcellular location of p16-positive signals (nuclear 
or cytoplasmic) was also estimated. The final score was 
calculated as the multiplication of percentage and staining 
intensity, resulting in scores of 0, 1, 2, 3, 4, 6, and 9 [27].
Statistical analysis
A linear-by-linear association test was performed 
to compare the status of stromal p16 expression between 
histological types and to determine whether stromal p16 
expression was significantly different according to degree 
of malignancy. Statistical analyses were performed using 
the SPSS Software Package (version 18.0; IBM SPSS, 
Chicago, IL, USA). Statistical significance was set at P 
< 0.05.
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